Suja Life Amends and Restates Credit Agreement with JPMorgan Chase Bank - News

Suja Life amended its credit agreement with JPMorgan Chase, reducing interest rates based on its leverage ratio. The company expects 2026 interest expense to fall to $18.0 million. According to CFO Jeff Pedersen, the refinancing lowers borrowing costs without adding debt.

Original reporting
Published Aug 24, 2026, 1:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 24, 2026, 2:21 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
MARKET
Neutral
AI market analysis
Mentioned
$SUJA
Relevance
6/10
AlphAI data visualization · based on abladvisor.com
Decision brief

The 30-second read

Med
01

Why it matters

The credit amendment improves the company's cost of capital without increasing debt, which could enhance profitability and support the stock.

02

Market read

A modest but positive corporate action for a small‑cap consumer stock.

03

What to watch

Potential covenant tightening or future rate hikes could affect the net benefit.

Relevance 6/10Novelty 6/10Timing: post‑announcement Aug 24 2026

Background

Suja Life is a publicly traded better‑for‑you beverage company that went public in 2024.

Market effects

May set a precedent for other niche beverage firms to seek cheaper financing.

Limited to U.S. small‑cap consumer sector.

Low; primarily affects Suja Life and its investors.

Counterpoint

If the lower spread is offset by higher leverage ratios, the benefit may be limited.

Key entities

  • Suja Life

    Public beverage maker (ticker SJA).

  • JPMorgan Chase Bank

    Administrative agent for the new credit agreement.

Related articles

Med

Suja Life’s Recent Volatility Masks A Longer Game In Functional Beverages

Suja Life's stock fell to $9 from $18 after lowering full-year guidance due to grocery channel weakness. Investors are exploring lawsuits, citing potential misleading information. Despite Q2 sales growth of 11.6% to $83.9M, sequential sales dropped 21%. The company remains optimistic about its long-term strategy in the functional beverage market, which is expected to reach $400B by 2034.

$SUJAMed

Suja Defies Grocery Slowdown With Double-Digit Sales Growth in Q2

Suja Life, Inc. (Nasdaq: SUJA) reported Q2 net sales up 11.6% year over year to $83.9 million, citing volume growth and improved distribution. Gross profit increased 9.9% to $39.2 million, or 46.7% of sales. The company raised its 2026 outlook to $360 to $369 million net sales from $326.6 million in 2025.

$SUJAMed

SUJA LIFE, INC. (SUJA): Results of Operations and Financial Condition

SUJA LIFE, INC. (SUJA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Suja Life Reports Second Quarter 2026 Financial Results Net sales increased 11.6% year-over-year to $83.9 million Updates fiscal year 2026 outlook OCEANSIDE, CA, August 4, 2026 – Suja Life, Inc. (NASDAQ: SUJA) (“Suja Life,” “Suja” or the “Company”), a leading better-for-you bever

$SUJAMedAI 9/10

Suja Life Reports First Quarter 2026 Financial Results

Suja Life (NASDAQ: SUJA) reported first-quarter 2026 net sales of $107.1 million, up 22.5% year over year from $87.4 million. Adjusted EBITDA rose 66.3% to $25.0 million, with margin expanding to 23.4%. Net income was $7.7 million versus a prior-year net loss. The company initiated 2026 guidance: net sales $367–$371 million and Adjusted EBITDA $70–$72 million.

$SUJAMed

Suja Life (NASDAQ:SUJA) Upgraded to “Strong-Buy” at Evercore

Evercore upgraded Suja Life (NASDAQ:SUJA) to a “strong-buy” rating in a Monday research note, according to Zacks.com. Other firms also initiated coverage: Goldman Sachs set a $31 target and a “buy,” Jefferies set a $25 target and a “buy,” and William Blair rated “outperform.” MarketBeat data show a consensus “Buy” and average target $26.67.

$NVDAMed

Here are Monday's biggest analyst calls: Nvidia, Apple, Tesla, Broadcom, Microsoft, IBM, Meta, Tyson Foods & more

Wall Street analysts issued multiple calls Monday. Goldman initiated HawkEye 360 as buy; Morgan Stanley upgraded Dell to equal weight; Wells Fargo upgraded Tandem Diabetes Care to overweight. Citizens initiated Microsoft at Market Outperform with a $550 target; Barclays initiated IBM at overweight with a $350 target. Cantor reiterated Tesla overweight; RBC reiterated Meta outperform. Broadcom was reiterated overweight by Morgan Stanley, raising its target to $485.